Skip to main content

Abiomed Inc

ABMDDelisted Dec 22, 2022
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0000815094

Abiomed Inc was delisted on Dec 22, 2022; its insiders filed their last Form 4 on Dec 27, 2022; 516 institutions reported holding it in 13F filings for Q3 2022, worth $10.6B in total; Maverick Capital was the only superinvestor holding it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 11:38 AM ET

Revenue flow, FY2022

Where the revenue went in FY2022, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.

Income statement

Each column is one fiscal year, newest first.

Income statement of Abiomed Inc, annual
Line itemFY2022FY2021FY2020FY2019FY2018
Period endMar 31, 2022Mar 31, 2021Mar 31, 2020Mar 31, 2019Mar 31, 2018
Filing10-K10-K10-K10-K10-K
ReportedApr 28, 2022Apr 29, 2021Apr 30, 2020May 2, 2019May 3, 2018
Revenue$1.03B$847.5M$840.9M$769.4M$593.7M
Cost of revenue$188.2M$161.9M$151.3M$129.6M$98.6M
Operating expenses–$456.1M$440.4M$415.1M$338.0M
Research and development$163.4M$121.9M$98.8M$93.5M$75.3M
Selling, general and administrative$423.5M$334.2M$341.6M$321.6M$262.7M
Operating income$140.7M$229.6M$249.2M$224.8M$157.1M
Income tax$54.1M$62.7M$53.8M$4.34M$48.3M
Net income$136.5M$225.5M$203.0M$259.0M$112.2M
EPS, basic$3.00$5.00$4.49$5.77$2.54
EPS, diluted$2.98$4.94$4.43$5.61$2.45
Weighted shares, basic45.4K45.1M45.2M44.9M44.2M
Weighted shares, diluted45.9M45.7M45.8M46.2M45.8M
Margins and growth
Operating margin13.6%27.1%29.6%29.2%26.5%
Net margin13.2%26.6%24.1%33.7%18.9%
Revenue growth, year over year+21.7%+0.8%+9.3%+29.6%+33.3%
Net income growth, year over year−39.5%+11.1%−21.6%+130.9%+115.2%

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Abiomed Inc, annual
Line itemFY2022FY2021FY2020FY2019FY2018
Period endMar 31, 2022Mar 31, 2021Mar 31, 2020Mar 31, 2019Mar 31, 2018
Filing10-K10-K10-K10-K10-K
ReportedApr 28, 2022Apr 29, 2021Apr 30, 2020May 2, 2019May 3, 2018
Cash and equivalents$132.8M$232.7M$192.3M$121.0M$43.0M
Short-term investments–$351.0M$250.8M$370.7M$319.3M
Accounts receivable$90.6M$97.2M$84.7M$90.8M$70.0M
Inventory–$81.1M$90.1M$80.9M$50.2M
Total current assets$976.5M$788.0M$635.9M$677.2M$494.3M
Property, plant and equipment$202.5M$197.1M$164.9M$145.0M$117.2M
Goodwill$76.8M$78.6M$32.0M$32.6M$35.8M
Total assets$1.67B$1.49B$1.22B$1.05B$786.4M
Accounts payable$35.3M$34.8M$32.8M$32.2M$23.6M
Total current liabilities$138.5M$129.0M$131.9M$106.0M$84.7M
Total liabilities$170.1M$164.7M$151.0M$117.5M$96.9M
Shareholders' equity$1.50B$1.33B$1.07B$936.9M$689.5M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Abiomed Inc, annual
Line itemFY2022FY2021FY2020FY2019FY2018
Period endMar 31, 2022Mar 31, 2021Mar 31, 2020Mar 31, 2019Mar 31, 2018
Filing10-K10-K10-K10-K10-K
ReportedApr 28, 2022Apr 29, 2021Apr 30, 2020May 2, 2019May 3, 2018
Operating cash flow$285.4M$274.6M$314.9M$252.2M–
Capital expenditures$35.8M$53.4M$44.0M$44.0M$55.9M
Free cash flow$249.6M$221.2M$270.9M$208.2M–
Depreciation and amortization$28.1M$24.1M$20.4M$14.1M$11.0M
Stock-based compensation$52.7M$47.0M$39.8M$54.5M$40.4M
Share buybacks–$11.3M$84.9M––
Investing cash flow-$381.0M-$223.3M-$125.5M-$116.5M–
Financing cash flow-$2.20M-$8.07M-$117.7M-$55.8M–
Net change in cash-$99.9M$40.4M$71.3M$78.0M$3.94M
Ratio
Stock-based compensation, % of revenue5.1%5.5%4.7%7.1%6.8%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Abiomed Inc by cover date
Cover dateShares outstandingChange in a yearFiling
Oct 28, 202245.1M−0.9%SEC
Jul 29, 202245.5M+0.2%SEC
May 12, 202245.6M+0.6%SEC
Jan 27, 202245.5M+0.6%SEC
Oct 22, 202145.5M+0.7%SEC
Jul 30, 202145.4M+0.7%SEC
May 14, 202145.3M+0.8%SEC
Jan 25, 202145.2M+0.4%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.